A randomized controlled trial of transition from insulin pump to multiple daily injections using insulin degludec

To evaluate two methods of transition from an insulin pump to multiple daily injections (MDI) using long‐acting insulin degludec (IDeg).

[1]  J. Snell-Bergeon,et al.  715-P: A Randomized, Controlled Trial of Transition from Insulin Pump to Multiple Daily Injections Using Insulin Degludec , 2021, Diabetes.

[2]  J. Rosenstock,et al.  Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment. , 2020, The New England journal of medicine.

[3]  I. Hirsch,et al.  Transition of Patients to and from Insulin Degludec: A Clinical Challenge. , 2019, The Journal of clinical endocrinology and metabolism.

[4]  G. Grunberger,et al.  Glycemic Outcomes in Adults With T1D Are Impacted More by Continuous Glucose Monitoring Than by Insulin Delivery Method: 3 Years of Follow-Up From the COMISAIR Study , 2019, Diabetes Care.

[5]  T. Danne,et al.  Clinical Use of Degludec in Children and Adolescents with T1D: A Narrative Review with Fictionalized Case Reports , 2019, Diabetes Therapy.

[6]  F. Doyle,et al.  Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range , 2019, Diabetes Care.

[7]  David M Maahs,et al.  State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018. , 2019, Diabetes technology & therapeutics.

[8]  J. Snell-Bergeon,et al.  Glycemic Outcomes with Early Initiation of Continuous Glucose Monitoring System in Recently Diagnosed Patients with Type 1 Diabetes. , 2019, Diabetes technology & therapeutics.

[9]  R. Wadwa,et al.  Performance of a Factory-Calibrated Real-Time Continuous Glucose Monitoring System Utilizing an Automated Sensor Applicator. , 2018, Diabetes technology & therapeutics.

[10]  Biao Xu,et al.  Comparative safety and efficacy of insulin degludec with insulin glargine in type 2 and type 1 diabetes: a meta-analysis of randomized controlled trials , 2018, Acta Diabetologica.

[11]  T. Bailey,et al.  Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial , 2017, JAMA.

[12]  R. Beck,et al.  Evaluation of Pump Discontinuation and Associated Factors in the T1D Exchange Clinic Registry , 2017, Journal of diabetes science and technology.

[13]  T. Heise,et al.  A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance , 2014, Clinical Pharmacokinetics.

[14]  T. Heise,et al.  Steady State is Reached within Two to Three Days of Once-daily Administration of Ultra-Long-acting Insulin Degludec , 2012 .

[15]  R. D. Steed,et al.  Switch to multiple daily injections with insulin glargine and insulin lispro from continuous subcutaneous insulin infusion with insulin lispro: a randomized, open-label study using a continuous glucose monitoring system. , 2005, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[16]  Karen M. Bolderman.  Putting Your Patients on the Pump , 2003 .

[17]  A. Zbrozek,et al.  The Validity and Reproducibility of a Work Productivity and Activity Impairment Instrument , 1993, PharmacoEconomics.

[18]  W. Polonsky,et al.  Development of a New Measure for Assessing Insulin Delivery Device Satisfaction in Patients with Type 1 and Type 2 Diabetes. , 2015, Diabetes technology & therapeutics.